This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00693472
First received: May 27, 2008
Last updated: April 21, 2017
Last verified: April 2017
  Purpose
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.

Condition Intervention Phase
Akathisia, Drug-Induced Antipsychotic Agents Movement Disorders Drug: Preladenant Drug: Placebo Drug: Anticholinergic agents or propanolol Drug: Haloperidol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Efficacy of SCH 420814 to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Part 1: Number of Participants With Akathisia [ Time Frame: Up to 13 days ]
    Incidence of akathisia is reported as the number of participants who experienced akathisia. Akathisia is defined as a score of 3 on the Barnes akathisia scale (BAS) for 3 consecutive intervals or an akathisia score (BAS) of ≥4 for any single day, or the use of a rescue medication within 13 days of initiating treatment with haloperidol and preladenant. The BAS is scored as follows: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness are rated on a 4-point scale from 0 - 3 and are summed yielding a total score ranging from 0 (no akathisia) to 9 (severe akathisia).

  • Part 2: Number of Participants Who Were Treatment Failures [ Time Frame: Up to 14 days ]
    Incidence of treatment failure is reported as the number of participants who were treatment failures. A treatment failure is defined as the failure to achieve at least a 1 point reduction from baseline in BAS score at 24 to 26 hours following study treatment. The BAS is scored as follows: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness are rated on a 4-point scale from 0 - 3 and are summed yielding a total score ranging from 0 (no akathisia) to 9 (severe akathisia).


Secondary Outcome Measures:
  • Part 1: Mean Global Clinical Impression at Day 14 [ Time Frame: Day 14 of Part 1 ]
    Global clinical impression (GCI) was administered to assess whether any deterioration is due to akathisia or uncontrolled psychoses. Score on a scale +2 to -2 (+2 represents much improvement, +1 some improvement, 0 no change, -1 some worsening, and -2 much worsening).

  • Part 1: Mean Positive and Negative Symptom Scale for Schizophrenia (PANSS) Total Score at Day 14 [ Time Frame: Day 14 of Part 1 ]

    The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal).

    For each item, symptom severity was rated on a 7-point scale, from 0=absent to 6=extreme. The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 0 to 180 with a higher score indicating greater severity of symptoms. Although the PANSS is traditionally scored with a range of 30-210, with a score of absent = 1 (for each item), for this analysis the range was set from 0-180, with a score of absent = 0 (for each item).


  • Part 2: Mean GCI at Day 14 [ Time Frame: Day 14 of Part 2 ]
    The GCI was administered to assess whether any deterioration is due to akathisia or uncontrolled psychoses. Score on a scale +2 to -2 (+2 represents much improvement, +1 some improvement, 0 no change, -1 some worsening, and -2 much worsening).

  • Part 2: PANSS Total Score at Day 14 [ Time Frame: Day 14 of Part 2 ]
    The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal). For each item, symptom severity was rated on a 7-point scale, from 0=absent to 6=extreme. The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 0 to 180 with a higher score indicating greater severity of symptoms. Although the PANSS is traditionally scored with a range of 30-210, with a score of absent = 1 (for each item), for this analysis the range was set from 0-180, with a score of absent = 0 (for each item).


Enrollment: 46
Study Start Date: August 15, 2007
Study Completion Date: January 9, 2009
Primary Completion Date: December 12, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1: Preladenant
Preladenant 25 mg every 12 hours for 13 days
Drug: Preladenant
Preladenant, one 25 mg capsule, administered orally every 12 hours
Other Name: SCH 420814
Drug: Anticholinergic agents or propanolol

Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.

Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Drug: Haloperidol
Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Placebo Comparator: Part 1: Placebo
Placebo every 12 hours for 13 days
Drug: Placebo
Matching placebo capsule administered orally every 12 hours
Drug: Anticholinergic agents or propanolol

Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.

Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Drug: Haloperidol
Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Experimental: Part 2: Preladenant
Preladenant 25 mg every 12 hours for 13 days
Drug: Preladenant
Preladenant, one 25 mg capsule, administered orally every 12 hours
Other Name: SCH 420814
Drug: Haloperidol
Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Active Comparator: Part 2: Standard of Care
Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
Drug: Anticholinergic agents or propanolol

Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.

Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Drug: Haloperidol
Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants or guardian must be willing to give written informed consent.
  • Part 1 Only: Participants with acute (not drug related) psychoses with a Positive and Negative Symptom Scale for Schizophrenia (PANSS) score of at least 60: schizophrenia, schizo-affective, schizo-manic, and acute mania with a history of previous treatment with neuroleptics.
  • Part 1 Only: Participants initiating haloperidol for the treatment of an acute psychotic episode at a dose of at least 7.5 mg per day.
  • Part 2 Only: Inpatient participants who have developed akathisia as a result of haloperidol at >=5 mg per day for the treatment of acute psychosis. The enrollment of participants receiving other neuroleptics is allowed only after consultation and agreement by the sponsor.
  • Participants of either sex and of any race between the ages of 18 and 65 years, inclusive.
  • Participant's clinical laboratory tests (complete blood count [CBC], blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to the investigator/sponsor. Participant's liver function test results (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT]) must not be elevated above the normal limits at Screening and on Day -1/1.
  • Participants must be free of any clinically significant disease other than psychosis that would interfere with the study evaluations.
  • Screening electrocardiogram (ECG) must be clinically acceptable to the investigator.
  • Female of childbearing potential must:

    • Have used a medically accepted method of contraception for 1 month (or abstained from sexual intercourse) prior to the screening period. An acceptable method of contraception includes one of the following:

      • condom (male or female) used with spermicide,
      • diaphragm or cervical cap used with spermicide and condom,
      • stable oral/transdermal/injectable hormonal contraceptive regimen without breakthrough uterine bleeding for 2 months prior to Screening visit and a condom used with spermicide,
      • intrauterine device (inserted at least 2 months prior to Screening visit) used with spermicide.

Note: Vasectomy of the partner is not considered sufficient contraception and one of the 4 bulleted methods listed above must be used.

  • Agree to use one of the accepted methods of contraception (listed above) during the trial (including the screening period prior to receiving trial medication), and for 1 month after stopping the trial medication.
  • Participants enrolled in the placebo arm of Part 1 and who developed akathisia may be eligible for Part 2 in the standard of care arm.

Exclusion Criteria:

  • Participants who have a positive screen for drugs with a high potential for abuse. Participants that screen positive for cannabis are permitted.
  • Participants who have previously received this compound.
  • Participants who are currently participating in another clinical study or have participated in a clinical study within 30 days (except participants enrolled in the Part 1 of the P05145 study).
  • Participants who are part of the study staff personnel or family members of the study staff personnel.
  • Participants with severe/uncontrolled hypertension will be excluded. Participants with hypertension well controlled on a stable dose of standard antihypertensive medication (excluding beta-blockers) will be eligible.
  • Participants with history of coronary artery disease including myocardial infarction (MI), or cerebrovascular disease (stroke, transient ischemic attack [TIA]), or peripheral arterial disease.
  • Participants with congestive heart failure or participants with ECGs consistent with ischemic heart disease, sick sinus syndrome or significant Q waves.
  • Participants who are found to be at immediate risk of suicide.
  • Female participants pregnant or nursing.
  • Participants treated by Clozapine will be excluded. A washout period of 6 months prior to dosing will be acceptable for study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00693472

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00693472     History of Changes
Other Study ID Numbers: P05145
MK-3814-019 ( Other Identifier: Merck protocol number )
Study First Received: May 27, 2008
Results First Received: February 8, 2017
Last Updated: April 21, 2017

Keywords provided by Merck Sharp & Dohme Corp.:
Antipsychotic Agents

Additional relevant MeSH terms:
Movement Disorders
Psychomotor Agitation
Akathisia, Drug-Induced
Central Nervous System Diseases
Nervous System Diseases
Dyskinesias
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Neurotoxicity Syndromes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Poisoning
Haloperidol
Haloperidol decanoate
Antipsychotic Agents
Propranolol
Cholinergic Antagonists
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 22, 2017